July 28, 2008 – CoMentis, Inc. and Astellas Pharma, Inc. announced that the companies will present six abstracts related to CTS21166 (ASP1702), a beta-secretase inhibitor for the treatment of Alzheimer’s disease, at the 2008 International Conference on Alzheimer’s Disease (ICAD) in Chicago, July 26-31. CTS21166 (ASP1702) is the first of several highly selective, potent and orally active beta-secretase inhibitors being developed by CoMentis and Astellas...
...-Single Dose Administration of the β-secretase Inhibitor CTS21166 (ASP1702) Reduces Plasma Aβ40 in Human Subjects
Poster #: P4-422
-Phase 1 Safety and Pharmacokinetic Profile of Single Doses of CTS21166 (ASP1702) in Healthy Males
Poster #: P4-454
-Pharmacokinetic / Pharmacodynamic Analysis of Plasma Aβ40 Reduction in Human Subjects Produced by the β-secretase Inhibitor CTS21166 (ASP1702)
Poster #: P4-455
-BACE1 Inhibitor CTS21166 (ASP1702) Penetrates Brain and Reduces Aβ Pathology in a Transgenic Mouse Model of Advanced AD
Poster #: P4-456
-Pharmacological Profile of BACE1 Inhibitor CTS21166 (ASP1702)
Poster #: P4-457
-Oral Administration of the BACE1 Inhibitor CTS21166 (ASP1702) Improves Cognition and Reduces Brain Aβ in Tg2576 Transgenic Mice
Poster #: P4-458
... CoMentis' Press Release -
